Medpoint Communications
Medpoint Communications is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
Phase 2, Open-Label Study in Subjects with Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- The study enrolled 9 participants across France, Israel, Italy, and the Republic of Korea.
- A May 2022 amendment changed the design from a single-arm two-stage study to a single-arm study with two interim analyses.
- Eligibility criteria were updated in amendments dated May 2022 and March 2023.
- A March 2023 amendment updated definitions for time to first deterioration in cough, pain, dyspnea, and physical functioning.
- Paper diary cards were added for sites in China in a March 2023 amendment.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine with Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
Sponsor Sanofi Vaccines US Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age
Sponsor Sanofi Pasteur Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(ies) (KEEPsAKE 2)
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase. Name: SKYPS
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A randomized, double blind, placebo controlled, parallel group, 52week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Medpoint Communications?
The 2026-10-09 snapshot links Medpoint Communications to 11 distinct CTIS trials. Recorded services include Document Portal, Project management, Safety reporting & pharmacovigilance, Training Vendor, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Medpoint Communications?
The most frequently recorded therapeutic areas are Dermatology, Immunology, Rheumatology, Respiratory. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Medpoint Communications conducted?
The linked trials record locations in 23 countries, including Germany, Spain, Italy, Poland, Portugal. These are trial locations, not confirmed office locations or countries where Medpoint Communications delivered services.
What can this page tell me about Medpoint Communications's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Medpoint Communications. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Medpoint Communications Inc.